William Hammond, MD
Medical Oncology · Burien, WANPI 1740277219
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $2,750 of the $3,072 with a category attached, or 89.5%. GSK accounts for 91.3% of it on its own, with 8 other manufacturers making up the rest. Reporting peaked in 2021 at $2,750 and has fallen 96.3% since, to $102 in 2024.
Across 12 payments — averaging $255.98 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$3K
- Stemline Therapeutics Inc.$110
- Taiho Oncology, Inc.$29
- Sobi, Inc$27
- Seagen Inc.$25
- AstraZeneca$23
- plus $53 from 3 others
What the payments were for
- Consulting fees$2,75090%
- Food & beverage$32210%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 3 | $2,804 |
| Stemline Therapeutics Inc. | 2 | $110 |
| Taiho Oncology, Inc. | 1 | $29 |
| Sobi, Inc | 1 | $27 |
| Seagen Inc. | 1 | $25 |
| AstraZeneca | 1 | $23 |
| Jazz Pharmaceuticals Inc. | 1 | $22 |
| Merck | 1 | $16 |
| Pharmaessentia USA Corporation | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- BLENREP$2,750
How this compares
$3,072 in reported general payments places this provider in the 55th percentile of 162 medical oncology providers in Washington.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other medical oncology in Burien
- Hakan KayaSpokane$2.2M
- Bart ScottSeattle$1.3M
- William BensingerLakewood$1.2M
- Petros GrivasSeattle$628K
- Vijayakrishna GadiSeattle$573K
- Evan YuSeattle$296K
- Siddhartha DevarakondaSeattle$215K
- David MaloneySeattle$150K
- Gary LymanSeattle$130K
- Joseph YeOlympia$115K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.